AbbVie Inc. logo

AbbVie Inc. - ABBV

NYSE:ABBV · ISIN US00287Y1091
StockHealthcareDrug Manufacturers - General🇺🇸 US

AbbVie Inc. stock, tokenized as ABBV.d by Dinari Inc., ABBVon by Ondo Finance and ABBVx by Backed Finance. Trades 24/7 on supported chains; redeemable 1:1 for the underlying with each issuer.

NYSE
$227.23
+1.02%+$2.29 today
Issued byOndo FinanceBacked FinanceDinari Inc.

About

AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.

Underlying metrics
Market cap$401.5B
Tokenized market cap$266.2K<0.01% of mkt cap
P/E (trailing)110.84
P/E (forward)13.99
EPS (TTM)$2.05
Beta0.31
Div. yield (fwd)3.04%
Div. yield (TTM)2.97%
Div. frequencyQuarterly
Ex-div dateApr 15, 2026
52-week range$181.73 — $244.81
Avg volume (90d)6.1M
Price/sales6.39
PEG ratio-2.41
Providers and contracts

Similar products